Key Points
- Insider sale: Fulgent Genetics insider Hanlin Gao sold 1,075 shares on Dec. 2 at an average of $28.33 (≈$30,455), trimming his stake by 0.11% to 952,890 shares; he also sold 943 shares on Nov. 28 and 535 shares on Nov. 24.
- Company results & outlook: Fulgent reported a quarterly beat (EPS $0.14 vs. -$0.22 est., revenue $84.07M vs. $81.43M) and set FY2025 guidance of 0.300 EPS, while the stock trades with a market cap of ≈$882.6M, a negative P/E, and an average analyst rating of "Hold" with a $32 target.
Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) insider Hanlin Gao sold 1,075 shares of the firm's stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total transaction of $30,454.75. Following the transaction, the insider directly owned 952,890 shares in the company, valued at approximately $26,995,373.70. The trade was a 0.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Hanlin Gao also recently made the following trade(s):
- On Friday, November 28th, Hanlin Gao sold 943 shares of Fulgent Genetics stock. The stock was sold at an average price of $29.57, for a total transaction of $27,884.51.
- On Monday, November 24th, Hanlin Gao sold 535 shares of Fulgent Genetics stock. The shares were sold at an average price of $30.47, for a total transaction of $16,301.45.
Fulgent Genetics Price Performance
Shares of NASDAQ:FLGT opened at $28.55 on Thursday. The stock has a market cap of $882.57 million, a price-to-earnings ratio of -20.45 and a beta of 0.64. Fulgent Genetics, Inc. has a 12 month low of $14.57 and a 12 month high of $31.04. The stock's 50 day moving average price is $25.24 and its 200 day moving average price is $22.17.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last issued its quarterly earnings results on Friday, November 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.36. Fulgent Genetics had a negative return on equity of 2.55% and a negative net margin of 13.62%.The company had revenue of $84.07 million for the quarter, compared to analysts' expectations of $81.43 million. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. On average, sell-side analysts expect that Fulgent Genetics, Inc. will post -0.85 EPS for the current year.
Institutional Trading of Fulgent Genetics
A number of institutional investors have recently bought and sold shares of FLGT. Signaturefd LLC increased its position in Fulgent Genetics by 60.4% in the 2nd quarter. Signaturefd LLC now owns 1,914 shares of the company's stock worth $38,000 after purchasing an additional 721 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Fulgent Genetics in the second quarter valued at approximately $49,000. Quantbot Technologies LP bought a new stake in Fulgent Genetics in the third quarter worth approximately $61,000. PNC Financial Services Group Inc. increased its stake in shares of Fulgent Genetics by 122.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,562 shares of the company's stock worth $60,000 after purchasing an additional 1,963 shares during the last quarter. Finally, State of Wyoming raised its holdings in shares of Fulgent Genetics by 111.1% during the 1st quarter. State of Wyoming now owns 6,564 shares of the company's stock valued at $111,000 after purchasing an additional 3,455 shares in the last quarter. Institutional investors and hedge funds own 48.06% of the company's stock.
Analysts Set New Price Targets
FLGT has been the subject of several analyst reports. Wall Street Zen raised Fulgent Genetics from a "hold" rating to a "buy" rating in a report on Saturday, November 15th. Raymond James Financial reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Fulgent Genetics in a research report on Friday, November 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Fulgent Genetics in a report on Wednesday, October 8th. Finally, Piper Sandler increased their price objective on Fulgent Genetics from $21.00 to $30.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $32.00.
Read Our Latest Research Report on FLGT
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
